Perinate herpes simplex viral infections may cause serious disease incidence and mortality. A number of the infections result from abscure cervical shedding of virus after a primary episode of genital HSV in the third trimester. Immune bodies to HSV-2 were found in approximately 20% of pregnant women, but only 5% report a history of symptomatic infection.
Primary cases of HSV and secondary cases near term or at the time of childbirth should be treated with antiviral therapy. Cesarean section should be performed if active HSV infection is present at the time of delivery.
Both symptomatic and asymptomatic primary genital HSV infections are associated with premature delivery and low birth weight children. Diagnosticating of perinate HSV may be difficult, but it should be suspected in any newborn with irritability, lethargy, fever or poor feeding at one week of age. Primary diagnosis is made by culturing the blood, cerebro-spinial fluid, urine and fluid from eyes, nose and mucous tunic. Actually all newborn infants suspected to have or who are diagnosed with HSV infection should be put under treatment with parenteral acyclovir.
Perinate herpes simplex virus (HSV) infections are transmitted from an infected mother, usually vertically, during childbirth. Introduction of infection is approximately 1 per 3,000 to 20,000 live births. A mother who detects a primary episode of genital HSV during the third trimester and who has not completed seroconversion by the onset of labor has a 33% chance of transmitting the infection to the child.
A mother detecting a secondary reactivation of HSV during the intrapartum period has approximately a 3% chance of transmitting the infection to her cheild. From amongst infected infants, only 30% have mothers who had symptomatic HSV or a sexual partner with clinical infection. Most perinate infections happen because of asymptomatic cervical shedding of virus, usually after a primary episode of HSV infection.
Frequency of occurrences worldwide of herpes simplex virus type 2 (HSV-2) seropositivity is anxiously high (about 25% seropositivity in USA). Immune bodies to HSV-2 were found in approximately 20% of ladies-in-waiting; however, only 5 have shown a history of symptomatic infection.
It’s worth mentioning that primary genital HSV infections during gestation can be detected at rates similar to those in nonpregnant women, and often these infections may be described as asymptomatic. There is a 2 to 3 percent seroconversion rate in pregnant women. Infection contamination occurs from an HSV-2-positive partner and is often traced to asymptomatic shedding of virus. Both symptomatic and asymptomatic primary genital HSV infections are associated with premature delivery and misborn infants. Due to wide spread of HSV among adults, physicians should take into consideration the risk of a primary HSV infection in a ladies-in-waiting and its potential consequences to the foetus.